News Headlines Article

New drug could dramatically reduce cholesterol
USA Today

The Food and Drug Administration on Thursday approved the second in a new class of cholesterol drugs that promises to dramatically lower cholesterol, although at a very high price.

Amgen’s Repatha, also known generically as evolocumab, belongs to a new class of injectable cholesterol fighters called PCSK9 inhibitors, which are man-made antibodies. The FDA last month approved the first of these drugs, Praluent, made by Sanofi and Regeneron Pharmaceuticals.

Both drugs will cost more than $14,000 a year.

Commands